Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial.

Abstract

BACKGROUND & AIMS:

Eosinophilic esophagitis (EoE) is caused by immunologic reactions to ingested/inhaled allergens. The diagnosis is considered if >or=15 eosinophils per high-powered field (eos/hpf) are detected in mucosal biopsies. Placebo-controlled studies have not been conducted to evaluate the safety and efficacy of oral viscous budesonide (OVB).

METHODS:

Children with EoE were randomly assigned to groups that were given OVB (n=15) or placebo (n=9). Patients<5 feet and >or=5 feet tall received 1 mg and 2 mg OVB daily, respectively. All patients received lansoprazole. Duration of treatment was 3 months, followed by repeat endoscopy and biopsies. Patients were classified as responders if their peak eosinophil counts were <or=6 eos/hpf, partial responders were 7-19 eos/hpf, and nonresponders were >or=20 eos/hpf. Baseline and post-treatment symptoms and endoscopic and histologic features were scored.

RESULTS:

Thirteen (86.7%) children given OVB (P<.0001) and none who received placebo (P=.3) were classified as responders. Mean pre-/post-treatment peak eosinophil counts were 66.7 and 4.8 eos/hpf, respectively, in the group given OVB (P<.0001); they were 83.9 and 65.6 eos/hpf, respectively, in the group given placebo (P=.3). In the group given OVB, there were significant reductions from baseline values in proximal (P=.002), mid (P=.0003), and distal (P=.001) esophageal eosinophilia. After OVB therapy, compared with baseline, the mean symptom (P=.0007), endoscopy (P=.0005), and histology scores improved (P=.0035) significantly.

CONCLUSIONS:

OVB is an effective treatment of pan-esophageal disease in children with EoE. OVB improves symptoms and endoscopic and histologic features. Proton pump inhibitor single therapy did not significantly improve esophageal eosinophilia or symptoms of EoE.

• Authors: Ranjan Dohil, Robert Newbury, Lyman Fox, John Bastian, Seema Aceves
• Journal: Gastroenterology (Gastroenterology) Vol. 139 Issue 2 Pg. 418-29 (Aug 2010) ISSN: 1528-0012 [Electronic] United States
• PMID: 20457157 (Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
• Copyright: Copyright (c) 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.

Chemical References

• 2-Pyridinylmethylsulfinylbenzimidazoles
• Anti-Inflammatory Agents
• Dosage Forms
• Proton Pump Inhibitors
• Transforming Growth Factor beta1
• Lansoprazole
• Budesonide

Topics

• 2-Pyridinylmethylsulfinylbenzimidazoles (therapeutic use)
• Administration, Oral
• Adolescent
• Anti-Inflammatory Agents (administration & dosage, chemistry)
• Biopsy
• Budesonide (administration & dosage, chemistry)
• Child
• Child, Preschool
• Dosage Forms
• Double-Blind Method
• Drug Therapy, Combination
• Eosinophilia (drug therapy, genetics, pathology)
• Esophagitis (drug therapy, genetics, pathology)
• Esophagoscopy
• Esophagus (chemistry, drug effects, pathology)
• Female
• Fibrosis
• Genotype
• Humans
• Immunohistochemistry
• Infant
• Lansoprazole
• Male
• Mucous Membrane (drug effects, pathology)
• Phenotype
• Placebo Effect
• Polymorphism, Single Nucleotide
• Promoter Regions, Genetic
• Proton Pump Inhibitors (pharmacology)
• Transforming Growth Factor beta1 (analysis, genetics)
• Treatment Outcome